MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527782 | Name: Rebamipide sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rebamipide is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals,[3] and temporarily activating genes encoding cyclooxygenase-2. Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa, and more recently, the small intestine, but not for naproxen-induced gastric damage.

Chemical Structure

Rebamipide sodium
Rebamipide sodium
CAS#169809-59-0 (sodium)

Theoretical Analysis

MedKoo Cat#: 527782

Name: Rebamipide sodium

CAS#: 169809-59-0 (sodium)

Chemical Formula: C19H14ClN2NaO4

Exact Mass: 370.0720

Molecular Weight: 392.77

Elemental Analysis: C, 58.10; H, 3.59; Cl, 9.03; N, 7.13; Na, 5.85; O, 16.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
111911-87-6 (deleted) 90098-04-7 (free acid) 169809-59-0 (sodium)
Synonym
Mucosta; OPC 12759; OPC-12759; OPC12759; Proamipide; Rebamipide; Rebator; Rebamipide sodium;
IUPAC/Chemical Name
sodium 2-[(4-Chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoate
InChi Key
GJOZVJFEEGNZID-UHFFFAOYSA-M
InChi Code
InChI=1S/C19H15ClN2O4.Na/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15;/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26);/q;+1/p-1
SMILES Code
O=C([O-])C(NC(C1=CC=C(Cl)C=C1)=O)CC2=CC(NC3=C2C=CC=C3)=O.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 392.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ballesteros-Sánchez A, Sánchez-González MC, De-Hita-Cantalejo C, Gutiérrez- Sánchez E, Rocha-de-Lossada C, Sánchez-González JM. The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials. J Clin Med. 2023 Nov 17;12(22):7155. doi: 10.3390/jcm12227155. PMID: 38002767; PMCID: PMC10672675. 2: Kovaleva A, Poluektova E, Maslennikov R, Karchevskaya A, Shifrin O, Kiryukhin A, Tertychnyy A, Kovalev L, Kovaleva M, Lobanova O, Kudryavtseva A, Krasnov G, Fedorova M, Ivashkin V. Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial. J Clin Med. 2023 Sep 20;12(18):6064. doi: 10.3390/jcm12186064. PMID: 37763004; PMCID: PMC10531936. 3: Dai X, Qin B, Zhang H, Zhao H, Zhao H, Huang L, Cheng J, Liu Z, Chen X. Determination of rebamipide in human plasma by a validated liquid chromatography-tandem mass spectrometry: Application in pharmacokinetics research. Pak J Pharm Sci. 2023 Jul;36(4(Special)):1281-1290. PMID: 37606017. 4: Eom Y, Chung SH, Chung TY, Kim JY, Choi CY, Yoon KC, Ko BY, Kim HK, Kim MK, Lee HK, Song JS, Hyon JY, Seo KY, Lee JS, Kim HM. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023 Aug 3;23(1):343. doi: 10.1186/s12886-023-03004-1. PMID: 37537533; PMCID: PMC10398964. 5: Bakulina NV, Tikhonov SV, Okovityi SV, Lutaenko EA, Bolshakov AO, Prikhodko VA, Nekrasova AS. [Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review]. Ter Arkh. 2023 Jan 16;94(12):1431-1437. Russian. doi: 10.26442/00403660.2022.12.202000. PMID: 37167190. 6: Elwany NE, El Salem A, Mostafa Mohamed N, Khalil SS, Mahmoud NM. Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling. Int Immunopharmacol. 2023 Jun;119:110269. doi: 10.1016/j.intimp.2023.110269. Epub 2023 May 4. PMID: 37148771. 7: Abdel-Fattah MM, Hassanein EHM, Sayed AM, Alsufyani SE, El-Sheikh AAK, Arab HH, Mohamed WR. Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats. Pharmaceuticals (Basel). 2023 Apr 2;16(4):533. doi: 10.3390/ph16040533. PMID: 37111290; PMCID: PMC10142103. 8: Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian J Ophthalmol. 2023 Apr;71(4):1598-1602. doi: 10.4103/IJO.IJO_2586_22. PMID: 37026308; PMCID: PMC10276702. 9: Jang DJ, Lee JH, Kim DH, Kim JW, Koo TS, Cho KH. The Development of Super- Saturated Rebamipide Eye Drops for Enhanced Solubility, Stability, Patient Compliance, and Bioavailability. Pharmaceutics. 2023 Mar 15;15(3):950. doi: 10.3390/pharmaceutics15030950. PMID: 36986811; PMCID: PMC10053044. 10: Won YH, Goo YT, Sin GH, Hong SH, Kim CH, Kim MJ, Lee TH, Choi YW. Immediate- release tablet formulation of rebamipide and a pharmacokinetic study in healthy human subjects. Int J Clin Pharmacol Ther. 2023 Jun;61(6):273-288. doi: 10.5414/CP204329. PMID: 36971320. 11: Correction to "Rebamipide potentially mitigates methotrexate-induced nephrotoxicity via inhibition of oxidative stress and inflammation: A molecular and histochemical study". Anat Rec (Hoboken). 2023 Aug;306(8):2208-2209. doi: 10.1002/ar.25184. Epub 2023 Mar 7. Erratum for: Anat Rec (Hoboken). 2021 Mar;304(3):647-661. PMID: 36880452. 12: Hasan S, Perween N, Saeed S, Kaur M, Gombra V, Rai A. Evaluation of 5% Amlexenox Oral Paste and Rebamipide Tablets in Treatment of Recurrent Apthous Stomatitis and Comparison with Dologel CT. Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):5228-5234. doi: 10.1007/s12070-020-01858-1. Epub 2020 Apr 27. PMID: 36742475; PMCID: PMC9895324. 13: Bae S, Huh KY, Oh J, Yu KS, Kim A. Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. Pharmaceuticals (Basel). 2023 Jan 16;16(1):132. doi: 10.3390/ph16010132. PMID: 36678630; PMCID: PMC9862565. 14: Jhun J, Moon J, Kim SY, Cho KH, Na HS, Choi J, Jung YJ, Song KY, Min JK, Cho ML. Rebamipide treatment ameliorates obesity phenotype by regulation of immune cells and adipocytes. PLoS One. 2022 Dec 27;17(12):e0277692. doi: 10.1371/journal.pone.0277692. PMID: 36574392; PMCID: PMC9794058. 15: Jia RJ, Wang XP, Zhang ZH, Cui HH, Qin R, Du DY, Liu Y. Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221130746. doi: 10.1177/10760296221130746. PMID: 36411982; PMCID: PMC9703470. 16: Oh DJ, Yoon H, Kim HS, Choi YJ, Shin CM, Park YS, Kim N, Lee DH, Ha YJ, Kang EH, Lee YJ, Kim N, Kim KJ, Liu F. The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study. Korean J Intern Med. 2022 Nov;37(6):1153-1166. doi: 10.3904/kjim.2021.216. Epub 2022 Nov 1. PMID: 36375487; PMCID: PMC9666262. 17: Corrigendum to 'Rebamipide suppresses TNF-α; mediated inflammation in vitro and attenuates the severity of dermatitis in mice'. FEBS J. 2023 Mar;290(6):1663-1664. doi: 10.1111/febs.16654. Epub 2022 Oct 26. Erratum for: FEBS J. 2015 Jun;282(12):2317-26. PMID: 36288791. 18: Zaky HS, Abdel-Sattar SA, Allam A, Ahmed HI. Further insights into the impact of rebamipide on gentamicin-induced nephrotoxicity in rats: modulation of SIRT1 and β-catenin/cyclin D1 pathways. Drug Chem Toxicol. 2023 Nov;46(5):851-863. doi: 10.1080/01480545.2022.2104867. Epub 2022 Jul 28. PMID: 35899710. 19: Teshigawara T, Meguro A, Mizuki N. Impact of Perioperative Dry Eye Treatment with Rebamipide Versus Artificial Tears on Visual Outcomes After Cataract Surgery in Japanese Population. Ophthalmol Ther. 2022 Aug;11(4):1479-1491. doi: 10.1007/s40123-022-00523-w. Epub 2022 May 19. PMID: 35588046; PMCID: PMC9253222. 20: Jang E, Park M, Jeong JE, Lee JY, Kim MG. Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease. Sci Rep. 2022 May 12;12(1):7839. doi: 10.1038/s41598-022-11505-0. PMID: 35552457; PMCID: PMC9098635.